Filana Therapeutics, Inc. (FLNA) Live Share Price, Invest From India

Filana Therapeutics, Inc. Stock Performance

as on April 28, 2026 at 6:59 am IST

Day's Low
Day's High
$1.56
Day's Price Range
$1.63
$1.57
0.64%
Downside
3.82%
Upside
52 Week's Low
52 Week's High
52-Week Price Range
$1.57
100.00%
Downside
-100.00%
Upside

Filana Therapeutics, Inc. share price movements today

Previous Close: $1.61
Open: $1.61
Volume: 520.5K
Day's Low - High: $1.56 - $1.63

Filana Therapeutics, Inc. Historical Returns

1 Month Return: -6.59 %
3 Month Return: 0 %
1 Year Return: 0 %
3 Year Return: 0 %
5 Year Return: 0 %

Filana Therapeutics, Inc. Stock Fundamentals & Key Indicators

Check Filana Therapeutics, Inc. market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$77.8M

EPS (TTM)

-1.02

Dividend Yield

0.00%

PE Ratio (TTM)

PEG Ratio

1.6222

Return On Equity TTM

-82.66%

Filana Therapeutics, Inc. vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Filana Therapeutics, Inc. with its industry peers.

Company	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin %
Filana Therapeutics, Inc.	NA	$77.8M	NA	NA	0.00%
Alnylam Pharmaceuticals Inc	BUY	$40.8B	114.94%	131.7	8.45%
Vertex Pharmaceuticals Inc	BUY	$109.5B	99.55%	28.1	32.94%
BeiGene, Ltd.	NA	$33.4B	NA	121.78	5.37%
Regeneron Pharmaceuticals Inc	BUY	$78.0B	52.62%	17.95	31.41%

Filana Therapeutics, Inc. Stock’s Investor Sentiment and Interest

Search interest for Filana Therapeutics, Inc. Stock has decreased by -40% in the last 30 days, reflecting a downward trend in search activity.

Time period: March 29, 2026 to April 28, 2026

Change:-40% versus previous 30 day period

Filana Therapeutics, Inc. Quarterly Profit & Loss

All numbers in Millions USD

	Mar 2008	Jun 2008	Sep 2008	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025
Total Revenue	-	-	-	-	-	-	-	-
Gross Profit	0	0	0	-	-	-	-	0
Operating Income	-	-	-	-29	-24	-45	-11	-13
EBITDA	-	-	-	-30	-24	-45	-11	-13
Interest Expense	-	-	-	-	-	-	-	-
Depreciation	-	-	-	0	0	0	0	0
Income Before Tax	-	-	-	-27	-23	-44	-10	-12
Income Tax Expense	-	-	-	-	-	-	-	-
Net Income	-1	-1	0	-27	-23	-44	-10	-12
Net Profit Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Filana Therapeutics, Inc. Annual Profit & Loss

All numbers in Millions USD

	Dec 2004	Dec 2005	Dec 2006	Dec 2007	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Revenue	-	-	-	-	-	-	-	-
Gross Profit	0	0	0	0	-	-	-	0
Operating Income	-	-	-	-	-80	-105	-141	-95
EBITDA	-	-	-	-	-80	-105	-141	-94
Interest Expense	-	-	-	-	-	-	-	-
Depreciation	-	-	-	-	1	1	1	0
Income Before Tax	-	-	-	-	-76	-97	-24	-90
Income Tax Expense	-	-	-	-	-	-	-	-
Net Income	-8	-1	-2	-3	-76	-97	-24	-90
Net Profit Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Filana Therapeutics, Inc. Quarterly Cash Flow

All numbers in Millions USD

	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025
Net Income	-27	-23	-44	-10	-12
Operating Cash Flow	-61	-11	-4	-6	-9
Investing Cash Flow	0	-	-	0	0
Financing Cash Flow	0	0	-	-	0
Change in Cash	-60	-11	-4	-6	-10

Filana Therapeutics, Inc. Annual Cash Flow

All numbers in Millions USD

	Dec 2023	Dec 2024	Dec 2025
Net Income	-97	-24	-90
Operating Cash Flow	-82	-116	-32
Investing Cash Flow	-	-	0
Financing Cash Flow	2	124	0
Change in Cash	-79	7	-33

Insights on Filana Therapeutics, Inc.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

NO EFFECT
Against Peers
In the last 1 year, Regeneron Pharmaceuticals, Inc. has given 21.9% return, outperforming this stock by 23.8%
NO EFFECT
Against Peers
In the last 3 years, Filana Therapeutics Inc has experienced a drawdown of -93.3%, however Alnylam Pharmaceuticals, Inc. resisted the overall trend and outperformed by 86.1%
NEGATIVE IMPACT
Price Dip
In the last 7 days, FLNA stock has moved down by -8.2%

About Filana Therapeutics, Inc.

Filana Therapeutics, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is in Phase 3 clinical trial to treat Alzheimer's disease; and investigational diagnostic product candidate is SavaDx, an early-stage program focused on detecting the presence of Alzheimer's disease from a small sample of blood. The company was formerly known as Cassava Sciences, Inc. and changed its name to Filana Therapeutics, Inc. in March 2026. The company was incorporated in 1998 and is based in Austin, Texas.

Organisation	Filana Therapeutics, Inc.
Headquarters	6801 N. Capital of Texas Highway, Austin, TX, United States, 78731
Industry	Biotechnology
CEO	Mr. Richard Jon Barry
E-voting on shares	Click here to vote

Key Management of Filana Therapeutics, Inc.

Name	Title
Dr. George Thornton Ph.D.	Senior Vice President of Technology
Mr. Jack Moore Ph.D.	Senior Vice President of Clinical Development
Dr. Angelique Bordey Ph.D.	Senior Vice President of Neuroscience
Dr. Joseph Hulihan M.D.	Chief Medical Officer
Mr. Richard Jon Barry	CEO, President & Director
Mr. Eric J. Schoen	Chief Financial Officer
Mr. R. Christopher Cook J.D.	Chief Operating & Legal Officer
Mr. Michael Zamloot	Senior Vice President of Technical Operations
Ms. Freda Nassif	Chief Business Officer & Chief Commercial Officer
Jaren Landen	Chief Clinical Development Officer

FAQs

What is Filana Therapeutics, Inc. share price today?

Filana Therapeutics, Inc. share price today is $1.57 as on April 28, 2026 at 1:29 am IST at the close of the market. Filana Therapeutics, Inc. share today touched a day high of $1.63 and a low of $1.56.

What is the 52 week high and 52 week low for Filana Therapeutics, Inc. share?

Filana Therapeutics, Inc. share touched a 52 week high of $ on January 1, 1970 and a 52 week low of $ on January 1, 1970. Filana Therapeutics, Inc. stock price today i.e. April 28, 2026 at 1:29 am IST is closed at $1.57,which is -Infinity% down from its 52 week high and Infinity% up from its 52 week low.

What is Filana Therapeutics, Inc.'s market capitalisation today?

Filana Therapeutics, Inc. market capitalisation is $0.00T as on April 28, 2026 at 1:29 am IST.

How to invest in Filana Therapeutics, Inc. Stock (FLNA) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Filana Therapeutics, Inc. on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Filana Therapeutics, Inc. Shares that will get you 0.9554 shares as per Filana Therapeutics, Inc. share price of $1.57 per share as on April 28, 2026 at 1:29 am IST.

What is the minimum amount required to buy Filana Therapeutics, Inc. Stock (FLNA) from India?

Indian investors can start investing in Filana Therapeutics, Inc. (FLNA) shares with as little as ₹94.19 or $1 (as of April 28, 2026 at 5:39 pm IST) using the INDmoney app.
For example: If you want to invest $10 or ₹941.90 in Filana Therapeutics, Inc. stock (as per the Rupee-Dollar exchange rate as on April 28, 2026 at 5:39 pm IST). Based on Filana Therapeutics, Inc. share’s latest price of $1.57 as on April 28, 2026 at 1:29 am IST, you will get 6.3694 shares of Filana Therapeutics, Inc.. Learn more about fractional shares .